JP5415762B2 - 新規製剤 - Google Patents

新規製剤 Download PDF

Info

Publication number
JP5415762B2
JP5415762B2 JP2008533471A JP2008533471A JP5415762B2 JP 5415762 B2 JP5415762 B2 JP 5415762B2 JP 2008533471 A JP2008533471 A JP 2008533471A JP 2008533471 A JP2008533471 A JP 2008533471A JP 5415762 B2 JP5415762 B2 JP 5415762B2
Authority
JP
Japan
Prior art keywords
tablet
metformin
dpp
tablets
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2008533471A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009510068A5 (enExample
JP2009510068A (ja
Inventor
ヤティンドラ・ジョシ
ジェイムズ・コワルスキー
ジェイ・パルティバン・ラクシュマン
アラン・エドワード・ロイス
ウェイ−キン・トン
マダヴ・ヴァサンタヴァダ
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37876819&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5415762(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2009510068A publication Critical patent/JP2009510068A/ja
Publication of JP2009510068A5 publication Critical patent/JP2009510068A5/ja
Application granted granted Critical
Publication of JP5415762B2 publication Critical patent/JP5415762B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2008533471A 2005-09-29 2006-09-25 新規製剤 Active JP5415762B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72262405P 2005-09-29 2005-09-29
US60/722,624 2005-09-29
PCT/US2006/037198 WO2007041053A2 (en) 2005-09-29 2006-09-25 Formulation comprising metformin and vildagli ptin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013146163A Division JP2013241429A (ja) 2005-09-29 2013-07-12 新規製剤

Publications (3)

Publication Number Publication Date
JP2009510068A JP2009510068A (ja) 2009-03-12
JP2009510068A5 JP2009510068A5 (enExample) 2009-11-05
JP5415762B2 true JP5415762B2 (ja) 2014-02-12

Family

ID=37876819

Family Applications (9)

Application Number Title Priority Date Filing Date
JP2008533471A Active JP5415762B2 (ja) 2005-09-29 2006-09-25 新規製剤
JP2013146163A Withdrawn JP2013241429A (ja) 2005-09-29 2013-07-12 新規製剤
JP2015201008A Active JP6270793B2 (ja) 2005-09-29 2015-10-09 新規製剤
JP2017202104A Withdrawn JP2018052945A (ja) 2005-09-29 2017-10-18 新規製剤
JP2019042906A Withdrawn JP2019131567A (ja) 2005-09-29 2019-03-08 新規製剤
JP2020151616A Active JP7194153B2 (ja) 2005-09-29 2020-09-09 新規製剤
JP2022065829A Withdrawn JP2022106763A (ja) 2005-09-29 2022-04-12 新規製剤
JP2023193231A Pending JP2024028702A (ja) 2005-09-29 2023-11-13 新規製剤
JP2024123496A Pending JP2024167195A (ja) 2005-09-29 2024-07-30 新規製剤

Family Applications After (8)

Application Number Title Priority Date Filing Date
JP2013146163A Withdrawn JP2013241429A (ja) 2005-09-29 2013-07-12 新規製剤
JP2015201008A Active JP6270793B2 (ja) 2005-09-29 2015-10-09 新規製剤
JP2017202104A Withdrawn JP2018052945A (ja) 2005-09-29 2017-10-18 新規製剤
JP2019042906A Withdrawn JP2019131567A (ja) 2005-09-29 2019-03-08 新規製剤
JP2020151616A Active JP7194153B2 (ja) 2005-09-29 2020-09-09 新規製剤
JP2022065829A Withdrawn JP2022106763A (ja) 2005-09-29 2022-04-12 新規製剤
JP2023193231A Pending JP2024028702A (ja) 2005-09-29 2023-11-13 新規製剤
JP2024123496A Pending JP2024167195A (ja) 2005-09-29 2024-07-30 新規製剤

Country Status (31)

Country Link
US (4) US20080227825A1 (enExample)
EP (1) EP1948149B2 (enExample)
JP (9) JP5415762B2 (enExample)
KR (2) KR101595169B1 (enExample)
CN (1) CN101277688B (enExample)
AR (1) AR055441A1 (enExample)
AT (1) ATE533481T1 (enExample)
AU (1) AU2006297444B2 (enExample)
BR (1) BRPI0616694B8 (enExample)
CA (1) CA2623011C (enExample)
CY (1) CY1112305T1 (enExample)
DK (1) DK1948149T4 (enExample)
EC (1) ECSP088318A (enExample)
ES (1) ES2377572T5 (enExample)
GT (1) GT200600426A (enExample)
IL (1) IL189856A (enExample)
JO (2) JOP20180109A1 (enExample)
MA (1) MA29854B1 (enExample)
MY (1) MY144975A (enExample)
NO (2) NO346101B1 (enExample)
NZ (1) NZ566430A (enExample)
PE (1) PE20070583A1 (enExample)
PH (1) PH12014500051B1 (enExample)
PL (1) PL1948149T5 (enExample)
PT (1) PT1948149E (enExample)
SG (4) SG166802A1 (enExample)
SI (1) SI1948149T2 (enExample)
TN (1) TNSN08146A1 (enExample)
TW (1) TWI389685B (enExample)
WO (1) WO2007041053A2 (enExample)
ZA (1) ZA200801773B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013241429A (ja) * 2005-09-29 2013-12-05 Novartis Ag 新規製剤

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
BRPI0608609A2 (pt) * 2005-05-10 2010-01-19 Novartis Ag processo de extrusço para preparaÇço de composiÇÕes com compostos terapÊuticos fracamente compressÍveis
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
AU2006333151B2 (en) * 2005-12-16 2010-03-04 Merck Sharp & Dohme Llc Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
EA030606B1 (ru) 2006-05-04 2018-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Способы приготовления лекарственного средства, содержащего полиморфы
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
FR2928836B1 (fr) * 2008-03-21 2011-08-26 Servier Lab Forme galenique secable permettant une liberation modifiee du principe actif
PE20140960A1 (es) * 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
AU2014262269B2 (en) * 2008-04-03 2017-02-02 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
MX2011002558A (es) 2008-09-10 2011-04-26 Boehringer Ingelheim Int Terapia de combinacion para el tratamiento de diabetes y estados relacionados.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR101054911B1 (ko) 2008-10-17 2011-08-05 동아제약주식회사 디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물
GB2465796A (en) * 2008-12-01 2010-06-02 Bee Kang Tan Metformin for the therapeutic use of conditions with raised serum amyloid A levels
CN102256976A (zh) 2008-12-23 2011-11-23 贝林格尔.英格海姆国际有限公司 有机化合物的盐形式
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
LT2395983T (lt) * 2009-02-13 2020-07-10 Boehringer Ingelheim International Gmbh Farmacinė kompozicija, apimanti sglt2 inhibitorių, dpp-iv inhibitorių ir, pasirinktinai, papildomą priešdiabetinį agentą, bei jos panaudojimas
EP2459531B1 (en) * 2009-07-31 2019-09-11 KRKA, D.D., Novo Mesto Granulate comprising vildagliptin and process for its preparation
EP2295083A1 (de) 2009-09-15 2011-03-16 Ratiopharm GmbH Pharmazeutische Zusammensetzung mit den Wirkstoffen Metformin und Sitagliptin oder Vildagliptin
WO2011039108A2 (en) 2009-09-30 2011-04-07 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives
EA030999B1 (ru) * 2009-10-02 2018-10-31 Бёрингер Ингельхайм Интернациональ Гмбх Применение фармацевтической композиции, включающей ингибитор дпп-4 и гидрохлорид метформина
UY32919A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
MX2012004673A (es) * 2009-10-23 2012-06-14 Merck Sharp & Dohme Composiciones farmaceuticas de combinaciones de inhibidores de dipeptidil peptidasa 4 con pioglitazona.
EA034869B1 (ru) 2009-11-27 2020-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
PE20121394A1 (es) * 2009-12-22 2012-10-29 Novartis Ag Formulacion que comprende derivados 1h-quinazolina-2,4-diona como antagonistas de receptores ampa, en forma de tabletas de liberacion inmediata y preparaciones de la misma
KR101819609B1 (ko) 2010-05-05 2018-01-17 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
KR20230051307A (ko) 2010-06-24 2023-04-17 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
TR201010683A1 (tr) * 2010-12-21 2012-07-23 Sanovel İlaç San. Ve Ti̇c. A.Ş. Vildagliptin formülasyonları.
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
MX366629B (es) 2011-07-15 2019-07-17 Boehringer Ingelheim Int Quinazolinas sustituidas, su preparación y su uso en composiciones farmacéuticas.
US20140302150A1 (en) * 2011-09-07 2014-10-09 Umit Cifter Dpp-iv inhibitor formulations
WO2013077824A1 (en) * 2011-11-23 2013-05-30 Mahmut Bilgic Preparation process for a formulation comprising metformin
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2014102715A1 (en) 2012-12-24 2014-07-03 Ranbaxy Laboratories Limited Pharmaceutical compositions comprising a biguanide and a low dose antidiabetic agent
RU2647421C2 (ru) * 2012-12-27 2018-03-15 Зентива Саглык Урунлеры Сан. Ве Тыдж. А.Ш. Способ сухого гранулирования для получения композиций метформина в виде таблеток и его композиции
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
PT2981271T (pt) 2013-04-05 2019-02-19 Boehringer Ingelheim Int Utilizações terapêuticas de empagliflozina
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HK1213818A1 (zh) 2013-04-05 2016-07-15 勃林格殷格翰国际有限公司 依帕列净的治疗用途
EA033286B1 (ru) 2013-04-18 2019-09-30 Бёрингер Ингельхайм Интернациональ Гмбх Способ лечения или отсрочки развития хронической болезни почек
WO2014184742A1 (en) 2013-05-13 2014-11-20 Ranbaxy Laboratories Limited Pharmaceutical compositions containing a biguanide and a low dose antidiabetic agent
JP5922310B2 (ja) * 2013-07-25 2016-05-24 株式会社三和化学研究所 医薬製剤
CN104546779A (zh) * 2013-10-14 2015-04-29 深圳海王药业有限公司 高药物荷载的枸橼酸西地那非片剂及其制备方法
EA032126B1 (ru) * 2013-12-23 2019-04-30 Крка, Д.Д. Ново Место Твердая фармацевтическая композиция, содержащая метформин и вилдаглиптин, и способы ее получения
CN103735544B (zh) * 2014-02-14 2015-08-19 南京华威医药科技开发有限公司 一种维达列汀/盐酸二甲双胍复方制剂的制备工艺
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
CN103845326B (zh) * 2014-03-24 2017-07-07 江苏奥赛康药业股份有限公司 维格列汀与二甲双胍的复方组合物及其制备方法
CN105582008A (zh) * 2014-11-14 2016-05-18 北京赛林泰医药技术有限公司 一种含有维格列汀和二甲双胍的组合物及其制备方法
KR102496851B1 (ko) * 2015-04-10 2023-02-08 제이더블유중외제약 주식회사 아나글립틴 또는 이의 약학적으로 허용 가능한 염 및 메트포르민 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물 및 그의 제조 방법
WO2017060861A2 (en) * 2015-10-07 2017-04-13 Steerlife India Private Limited Rapidly disintegrating tablet compositions of dpp-iv inhibitors with low mineral content
CN105769796B (zh) * 2016-05-04 2019-06-04 杭州百诚医药科技股份有限公司 一种含有维格列汀和盐酸二甲双胍的药物制剂及其制备方法
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition
CN106432026A (zh) * 2016-09-12 2017-02-22 重庆医科大学 一类对糖尿病具有潜在治疗活性的化合物
CN106421794A (zh) * 2016-09-27 2017-02-22 黑龙江珍宝岛药业股份有限公司 一种用于治疗ⅱ型糖尿病的药物组合物及其制备方法
JP7625363B2 (ja) 2016-11-10 2025-02-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物、治療方法及びその使用
TW201938147A (zh) * 2017-12-18 2019-10-01 德商拜耳廠股份有限公司 阿卡波糖與甲福明之固定劑量組合錠劑配製物及其製法
TR201722603A2 (tr) * 2017-12-28 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Metformi̇n ve si̇tagli̇pti̇n i̇çeren sicak eri̇tme ekstrüzyonu i̇le gerçekleşti̇ri̇len tablet formülasyonlari
KR102622198B1 (ko) * 2018-03-30 2024-01-09 한미약품 주식회사 빌다글립틴을 함유하는 경구용 고형제제 및 그의 제조 방법
EP3793529A1 (en) 2018-05-18 2021-03-24 Galenicum Health S.L.U. Stable pharmaceutical compositions of dpp-iv inhibitors in combination with metformin in the form of immediate release tablets
KR102647472B1 (ko) * 2018-07-31 2024-03-14 한미약품 주식회사 디펩티딜 펩티다아제-4 억제제 및 메트포르민을 포함하는 경구용 고형 복합제제 및 이의 제조방법
GR1009644B (el) * 2018-09-25 2019-11-12 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει βιλνταγλιπτινη και μετφορμινη και μεθοδος για την παρασκευη αυτου
RU2712097C1 (ru) * 2018-09-28 2020-01-24 Общество с ограниченной ответственностью "Необиотек" Ингибитор дипептидилпептидазы-4 для лечения сахарного диабета 2-го типа, соединения (варианты)
WO2020098904A1 (en) 2018-11-12 2020-05-22 Pharmaceutical Oriented Services Ltd Dosage form containing metformin and a dipeptidyl peptidase iv inhibitor
KR20220004026A (ko) * 2019-03-25 2022-01-11 더 조지 인스티튜트 포 글로벌 헬스 저 투여량 3종 병용 제제
KR102693304B1 (ko) * 2019-04-16 2024-08-08 한미약품 주식회사 빌다글립틴 염산염 함유 복합 제제의 안정성 개선을 위한 포장재
TR201913472A2 (tr) 2019-09-06 2021-03-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vi̇ldagli̇pti̇n ve metformi̇n i̇çeren bi̇r kombi̇nasyon
US12351847B2 (en) 2019-10-16 2025-07-08 Bayer Aktiengesellschaft Methods for the improved formation of acarbose
KR102362342B1 (ko) 2020-01-31 2022-02-14 주식회사 경보제약 빌다글립틴 및 메트포민 포함하는 복합 정제
KR102856843B1 (ko) * 2020-03-30 2025-09-08 한미약품 주식회사 시타글립틴, 다파글리플로진, 및 메트포르민을 포함하는 경구용 복합정제
TR202009949A1 (tr) * 2020-06-25 2022-01-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vi̇ldagli̇pti̇n ve metformi̇n hci i̇çeren bi̇r fi̇lm kapli tablet
WO2022070209A1 (en) * 2020-09-29 2022-04-07 Dr. Reddy's Laboratories Limited Biphasic release fixed dose combination formulations
CN114306267A (zh) * 2020-09-30 2022-04-12 深圳翰宇药业股份有限公司 一种西格列汀二甲双胍片制剂及其制备方法
GB2599950A (en) * 2020-10-16 2022-04-20 Zentiva Ks Pharmaceutical compositions with low amounts of nitrosamine impurities and methods for producing the same
JP2022151564A (ja) * 2021-03-26 2022-10-07 東和薬品株式会社 薬効成分としてビルダグリプチンおよびメトホルミンを含む錠剤
WO2022211762A1 (en) 2021-03-29 2022-10-06 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi The film coated tablet of vildagliptin and metformin hydrochloride
JP2022182181A (ja) * 2021-05-27 2022-12-08 キョーリンリメディオ株式会社 ビルダグリプチン含有医薬品

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
US3621097A (en) * 1970-03-30 1971-11-16 Jan Marcel Didier Aron Samuel Method and compositions for treatment of mental illness
DE3720757A1 (de) * 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
IT1276130B1 (it) * 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
DE19823831A1 (de) * 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
CO5150173A1 (es) * 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
CA2673615C (en) * 2000-01-21 2013-07-16 Novartis Ag Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
CA2424770A1 (en) * 2000-10-06 2003-04-03 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation
JP4848558B2 (ja) * 2001-05-08 2011-12-28 トーアエイヨー株式会社 塩酸メトホルミン含有速放性錠剤
FR2824825B1 (fr) * 2001-05-15 2005-05-06 Servier Lab Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN1805738A (zh) * 2003-06-16 2006-07-19 兰贝克赛实验室有限公司 持续释放的二甲双胍片剂
NZ548351A (en) * 2004-01-20 2009-08-28 Novartis Ag Direct compression formulation and process
AU2005299808B2 (en) * 2004-10-25 2009-08-20 Novartis Ag Combination of DPP-IV inhibitor, PPAR antidiabetic and metformin
GT200600008A (es) * 2005-01-18 2006-08-09 Formulacion de compresion directa y proceso
GT200600218A (es) * 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
JOP20180109A1 (ar) * 2005-09-29 2019-01-30 Novartis Ag تركيبة جديدة

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013241429A (ja) * 2005-09-29 2013-12-05 Novartis Ag 新規製剤
JP2016029079A (ja) * 2005-09-29 2016-03-03 ノバルティス アーゲー 新規製剤
JP2018052945A (ja) * 2005-09-29 2018-04-05 ノバルティス アーゲー 新規製剤
JP2019131567A (ja) * 2005-09-29 2019-08-08 ノバルティス アーゲー 新規製剤
JP2021006534A (ja) * 2005-09-29 2021-01-21 ノバルティス アーゲー 新規製剤
JP7194153B2 (ja) 2005-09-29 2022-12-21 ノバルティス アーゲー 新規製剤

Also Published As

Publication number Publication date
AR055441A1 (es) 2007-08-22
PL1948149T5 (pl) 2023-03-06
JOP20180109A1 (ar) 2019-01-30
ZA200801773B (en) 2009-09-30
PT1948149E (pt) 2012-02-16
CY1112305T1 (el) 2015-12-09
US20140287040A1 (en) 2014-09-25
KR20080056171A (ko) 2008-06-20
TWI389685B (zh) 2013-03-21
ECSP088318A (es) 2008-04-28
HK1121372A1 (en) 2009-04-24
JP2024167195A (ja) 2024-12-03
JP2021006534A (ja) 2021-01-21
PH12014500051A1 (en) 2015-01-12
IL189856A (en) 2016-02-29
AU2006297444B2 (en) 2010-08-12
BRPI0616694B1 (pt) 2020-03-10
TNSN08146A1 (en) 2009-07-14
PH12014500051B1 (en) 2015-01-12
SG10202011759VA (en) 2021-01-28
EP1948149A2 (en) 2008-07-30
KR101391085B1 (ko) 2014-04-30
KR20140021049A (ko) 2014-02-19
JP2024028702A (ja) 2024-03-05
TW200800168A (en) 2008-01-01
CN101277688B (zh) 2011-12-14
JP7194153B2 (ja) 2022-12-21
BRPI0616694B8 (pt) 2021-05-25
JP2016029079A (ja) 2016-03-03
KR101595169B1 (ko) 2016-02-18
US20130052239A1 (en) 2013-02-28
ES2377572T3 (es) 2012-03-29
RU2483716C9 (ru) 2021-08-10
DK1948149T4 (da) 2022-10-10
NO344875B1 (no) 2020-06-08
US20110045062A1 (en) 2011-02-24
DK1948149T3 (da) 2012-02-20
EP1948149B2 (en) 2022-07-06
ATE533481T1 (de) 2011-12-15
PL1948149T3 (pl) 2012-04-30
JP2013241429A (ja) 2013-12-05
JP2018052945A (ja) 2018-04-05
SI1948149T1 (sl) 2012-03-30
IL189856A0 (en) 2008-12-29
JP6270793B2 (ja) 2018-01-31
JP2019131567A (ja) 2019-08-08
ES2377572T5 (es) 2022-11-08
RU2008116316A (ru) 2009-11-10
CA2623011C (en) 2014-04-15
SG10201809313WA (en) 2018-11-29
WO2007041053A2 (en) 2007-04-12
SI1948149T2 (sl) 2022-10-28
AU2006297444A1 (en) 2007-04-12
MY144975A (en) 2011-11-30
NO346101B1 (no) 2022-02-14
NO20200301A1 (no) 2008-06-27
JP2022106763A (ja) 2022-07-20
CN101277688A (zh) 2008-10-01
US20080227825A1 (en) 2008-09-18
GT200600426A (es) 2007-05-21
SG166802A1 (en) 2010-12-29
RU2483716C2 (ru) 2013-06-10
NZ566430A (en) 2011-10-28
MA29854B1 (fr) 2008-10-03
JP2009510068A (ja) 2009-03-12
PE20070583A1 (es) 2007-07-16
NO20082048L (no) 2008-06-27
BRPI0616694A2 (pt) 2011-06-28
EP1948149B1 (en) 2011-11-16
SG10201401826TA (en) 2014-10-30
CA2623011A1 (en) 2007-04-12
WO2007041053A3 (en) 2008-03-13
JO3795B1 (ar) 2021-01-31

Similar Documents

Publication Publication Date Title
JP7194153B2 (ja) 新規製剤
KR20080018257A (ko) Ｄｐｐ－ｉｖ 억제제 및 글리타존의 직접 압축 제제, 및방법
RU2821230C2 (ru) Новый состав
HK1121372B (en) Formulation comprising metformin and vildagliptin
MX2008003974A (en) Formulation comprising metformin and vildagli ptin

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090910

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090910

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20120329

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120403

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120612

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120905

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120912

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121109

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121210

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130712

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20130712

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20130730

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130911

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20130917

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131022

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131114

R150 Certificate of patent or registration of utility model

Ref document number: 5415762

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250